In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marker Therapeutics Inc.

markertherapeutics.com

Latest From Marker Therapeutics Inc.

Finance Watch: VC Tally Hits $14.5bn For 2018, Beating 2017 With A Quarter Left To Go

US VC investment in biopharma totaled $14.5bn in the first three quarters of 2018, exceeding the full-year 2017 sum of $11.9bn. UK biotech cash also is rising, benefitting new companies like Sitryx.
StartUps and SMEs Financing

Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.

Financing Business Strategies

Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina

Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.

Deals ImmunoOncology

Pipeline Watch: Phase III Readouts For Talazoparib, Ampion, Avatrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • TapImmune Inc.
  • Eduverse.com
  • GeneMax Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Marker Therapeutics Inc.
  • Senior Management
  • Peter L Hoang, Pres. & CEO
    Michael J Loiacono, CFO
    Richard Kenney, MD, Acting CMO
    Ann Leen, PhD, CSO
  • Contact Info
  • Marker Therapeutics Inc.
    Phone: (904) 862-6490
    5 West Forsyth St.
    Jacksonville, FL 32202
    USA
UsernamePublicRestriction

Register